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Abstract
Background: Multiple myeloma is an uncommon cancer with a poor prognosis. Its incidence is expected to
increase due to ageing populations and better diagnosis, and new treatments have been developed to improve
survival. Our objective was to investigate trends in the epidemiology and survival of multiple myeloma for South
East England.
Methods: Data on 15,010 patients diagnosed with multiple myeloma between 1985 and 2004 was extracted from
the Thames Cancer Registry database. We calculated the yearly age-standardised incidence rates for males and
females and age-specific incidence rates in 10-year age groups for both sexes combined. We also explored
geographical variation in incidence across primary care trusts. We then used period analysis to calculate trends in
1- and 5-year relative survival over the 15 years 1990-2004, comparing survival by sex and by age group 59 years
and below versus 60 years and above. Finally, we investigated 5-year relative survival for the period 2000-2004 by
socio-economic deprivation, assigning patients to quintiles of deprivation using the Income Domain of the Index
of Multiple Deprivation 2004 based on postcode of residence.
Results: The incidence of multiple myeloma was higher in males than in females and in patients over 70,
throughout the period 1985-2004. No obvious geographical pattern of incidence by primary care trust emerged.
The 1- and 5-year relative survival of male and female patients increased in both age groups and was statistically
significant in males aged over 60. There was a tendency for better survival in patients resident in the most affluent
areas, but this did not reach statistical significance.
Conclusions: The trends in incidence of multiple myeloma in males and females are similar to that reported from
other western populations. Relative survival was higher for younger patients although we found significant
improvements in 1-year relative survival for male patients over 60 years old. The improved survival demonstrated
for patients of all ages is likely to reflect increased detection, earlier diagnosis and the introduction of new
treatments. Future studies should investigate the influence of ethnicity on incidence and survival, and the effect of
specific treatments on survival and quality of life.
Background
Multiple myeloma is the second most common haema-
tological cancer accounting for 10-15% of these malig-
nancies [1]. The disease is a proliferation of malignant
plasma cells within the bone marrow; these cells usually
produce abnormal immunoglobulin-related proteins in
the serum (paraprotein) and urine (Bence Jones protein).
The disease is generally diffuse (hence “multiple” mye-
loma) but focal deposits are common, typically involving
the spine, ribs, skull and pelvic bones. Patients present
with non-specific symptoms such as fatigue, anaemia
and bone pain, so many patients have advanced disease
at the time of diagnosis [2]. The disease is essentially
one that affects older adults (median age at presentation
70 years) and it is rare for it to be diagnosed in those
under 40 years old [3].
S i n c em u l t i p l em y e l o m ai sar e latively rare disease its
aetiology has been difficult to assess. Established risk
factors include increasing age, male sex and a positive
family history. In addition, incidence rates are consis-
tently higher in black ethnic groups world-wide [4]
and have recently been shown to be higher in black
ethnic groups in England [5]. In 2004, the age-adjusted
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100,000 standard European population for males and
3.8 per 100,000 population for females [6]. This rate is
similar to that in Canada, Sweden and white Ameri-
cans, [7] but higher than that in Asia populations [8].
Increases in incidence rates are also likely due to bet-
ter diagnosis (immunohistochemistry and serum free
light chain assays) and more accurate death certifica-
tion. The number of cases is expected to increase in
developed countries in line with the predicted increase
of life expectancy of their populations [9].
Significant improvements in one-year relative survi-
val have been observed since the 1970s [10,11] due to
new treatments. A study by Phekoo and colleagues
[12] developed a clinician-reported dataset for a popu-
lation of 5.4 million part of South East England. They
found that the incidence in 1999 to 2000 was slightly
higher than previously reported in the UK, and survival
was significantly reduced in patients older than 65
years old compared with younger patients. No marked
association between socio-economic deprivation and
patient survival was reported in England and Wales for
the period 1986 to 1990 [10]. However, a recent analy-
sis for 2000-2001 found that patients living in affluent
areas have a 5-year relative survival of more than 10
percentage points higher compared to those living in
the most deprived areas, and that the socio-economic
difference in survival has widened between 1990 and
2000 [13].
In this study we used data from the Thames Cancer
Registry area covering a population of 14.2 million living
in South East England and report trends in the inci-
dence and survival over a longer time period dating
back to 1985.
We aimed to provide new information that would help
guide clinical and health service planning to meet
patient needs within the geographical area of South East
England.
Our objectives were:
1) To describe trends in the incidence of multiple
myeloma for men and women in South East England
between 1985 and 2004.
2) To explore geographical variation in the incidence
of multiple myeloma at the level of individual pri-
mary care trust between 1995 and 2004.
3) To describe trends in the relative survival for
multiple myeloma for men and women for the per-
iod 1990 to 2004.
4) To investigate the relationship between relative
survival and socio-economic deprivation of area of
residence between 2000 and 2004.
Methods
During the study period 1985 to 2004 the Thames Can-
cer Registry (TCR) covered the areas of London, Surrey,
Sussex, Kent, Essex and Hertfordshire including a resi-
dent population of 14.2 million people. The population
in London is ethnically diverse including 11% from
Black ethnic groups, 12% from Asian ethnic groups and
71% from White groups, according to the 2001 Census.
These proportions compare with those for the whole
TCR area of South East England of 6% Black, 7% Asian
and 83% White. In this area cancer registration is
initiated by clinical and pathology information received
from hospitals and by information on deaths provided
by the National Health Service Central Register through
the Office for National Statistics. Trained data collection
officers collect further information on demographic
details, disease stage and treatment received within the
six months following diagnosis from the medical records
of individual patients. In addition information from the
South Thames Haematology Register was included from
1998, based on data supplied directly from clinical
teams to the cancer registry. Data are checked in the
registry to ensure that they refer to new malignancies
rather than a recurrence of already registered cases, con-
tinuously added to a central database and quality
assured. Information from death certificates of patients
on the cancer register allows the calculation of survival
after diagnosis.
Cancer registries in England have legal support to col-
lect data relating to cancer under Section 251 of the
NHS Act 2006 and formerly under Section 60 of the
Health and Social Care Act 2001. The study used an
anonymised dataset and separate ethical approval was
not required.
We extracted data on 15,010 patients diagnosed with
multiple myeloma (ICD-O M97323) between 1985 and
2004 from the registry database. We tabulated the
demographic characteristics of these patients and calcu-
lated the age-standardised incidence rate for men and
women for South East England using the European stan-
dard population. We used data on the size of the resi-
dent population to compute the age-specific incidence
rates for multiple myeloma in each year for each of the
age groups, less than 40, 40 to 49, 50 to 59, 60 to 69, 70
to 79 and 80 or older.
I nt h ea r e at h e r ea r e4 6p r i m a r yc a r et r u s t sr e s p o n s i -
ble for commissioning and funding health services for
the needs of their local communities. We explored var-
iation in the incidence across the population of primary
care trusts (PCTs) by calculating the age-standardised
incidence rates for each area, using the boundaries
established by the NHS in October 2006. The PCT
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played on maps, using geographic information system
(GIS) software.
To determine the trend in survival over the period
1990 to 2004, we used period analysis to calculate the
relative survival for multiple myeloma in men and
women separately. The period analysis method [14]
enables cross-sectional analysis by including all patients
about whom there is information on the database during
the follow-up period of interest, even if diagnosis
occurred prior to this period. This enables the most
recent data on patients diagnosed in the last years of the
study period to be included in the analysis. The end
point for the relative survival analysis in any period does
not rely on the accurate classification of the cause of
death. This provides a measure of total excess mortality
associated with the diagnosis of multiple myeloma. Rela-
tive survival is the observed survival in the patient
group divided by the expected survival of a comparable
group from the population, in any given period,
matched by age and sex. We grouped the patients into
those diagnosed at ages 59 years and below and 60
years and over. We calculated relative survival estimates
for the periods of follow-up 1990 to 1994, 1995 to 1999
and 2000 to 2004, excluding patients whose registrations
were based only on their death certificate.
Finally, we investigated 5-year relative survival for the
period 2000-2004 by socio-economic deprivation, assign-
ing patients to quintiles of deprivation using the Income
Domain of the Index of Multiple Deprivation 2004 [15]
based on postcode of residence. The overall trend for
the relative survival estimates was assessed by test for
trend over socio-economic levels and over the three
time periods.
Results
Table 1 shows the demographic characteristics of
patients with multiple myeloma diagnosed between 1985
and 2004 in South East England. Fifty-two percent of
patients were male and 82% were older than 60 years.
The median age at diagnosis was 72 years for this
population.
Figure 1 shows the age-standardised incidence rates
for males and females in South East England. Overall
rates did not increase during the study period. Through-
out the period 1985 to 2004 the age-standardised inci-
dence rate in males was higher than for females.
Figures 2 shows the age specific incidence rates for
males and females combined in different age groups.
The highest rates were in the groups aged over 60 years.
There was no obvious geographical patterning of inci-
d e n c eb yp r i m a r yc a r et r u s to fr e s i d e n c e( F i g u r e3 ) .
Higher incidence rates were found in the inner London
PCTs but were not exclusive to these areas.
Relative survival was higher for the younger age group
than for the older group in both males and females (Fig-
ures 4). There was also evidence of increasing relative
survival over time for both sexes in each age group. Fig-
ure 4 shows the 1- and 5-year estimates of relative sur-
vival for patients aged 59 and below at diagnosis, by sex
for the three follow-up periods. This group had a higher
overall relative survival in all of the follow-up periods.
For males the 5-year relative survival increased from
36% to 46% and 47%, with the largest improvement
being between the 1990-1994 and 1995-1999 periods of
follow-up. For females a steady increase was seen for
each of the follow-up periods with 5-year relative survi-
val yielding figures of 40% to 45% and 56%, respectively.
Figure 4 shows the 1- and 5-year estimates of relative
survival of patients aged 60 and above, by sex for the
three follow-up periods. This older age group had a
lower overall relative survival in all follow-up periods.
For males the 5-year relative survival increased from
14% to 18% and 23%. Similarly in females, survival
increased from 17% to 18% and 21% for each of the per-
iods of follow-up. The 1-year estimates of relative survi-
val showed a very similar pattern of improving survival
over each of the three periods of follow-up, with a sig-
nificant improvement in survival trend in the 1-year
estimates in patients aged 60 and over. We also found
an improvement in 5-year survival in males in the older
age group over the time period.
Figure 5 shows the relationship between 5-year rela-
tive survival and socio-economic deprivation for area of
residence for the period 2000 to 2004. In both males
and females there was a tendency for higher survival in
patients resident in the most affluent areas, (males trend
p = 0.09, females trend p = 0.07).
Table 1 Characteristics of patients with multiple
myeloma diagnosed between 1985 and 2004, in South
East England
Characteristics Number of patients (%)
Sex
Males 7733 (52)
Females 7277 (48)
Total 15010 (100)
Age group
0-39 137 (1)
40-49 596 (4)
50-59 1854 (12)
60-69 3510 (23)
70-79 4989 (33)
80+ 3924 (26)
Total 15010 (100)
Figures are numbers (with percentages in parenthesis) of patients.
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Figure 1 Age-standardised incidence rates for multiple myeloma, South East England 1985-2004.
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Figure 2 Age specific incidence rates for multiple myeloma, male and female combined, South East England 1985-2004.
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In this study using cancer registration data for South
East England we found that the incidence of multiple
myeloma was higher in males than in females over the
period 1985 to 2004. The incidence rates increased shar-
ply with age and were highest for men and women aged
over 80, with relatively few cases occurring in patients
less than 40 years old. Both findings are consistent with
the well documented risk factors for multiple myeloma
of advanced age and male sex. The overall incidence fig-
ures for South East England are also similar to those
previously reported for the UK [6]. No obvious geogra-
phical pattern of incidence by primary care trust
emerged, although higher rates in some inner London
PCTs may be due in part to a higher proportion of peo-
ple from Black ethnic groups resident in these areas.
Figure 3 Age-standardised incidence rates for multiple myeloma for primary care trusts in South East England, 1995-2004.
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Figure 4 Relative survival by period of follow-up for patients with myeloma in South East England 1990-2004. 1- and 5-year estimates
with 95% confidence intervals.
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trend for improvement in the survival of all patients
between 1990 and 2004, with each successive five-year
period showing improvement on the previous 1-year
survival. Although this is generally consistent with the
results of other recent large studies of similar-sized
populations, our results differ in showing a significant
improvement in 1-year survival in patients over 60 years
old, though shorter than for those younger than 60.
This may in part be due to the larger number of
patients in the older age group. By comparison, a Swed-
ish study [11] investigating relative survival over a 30-
year period from 1973 to 2003 found that while 1-year
survival had significantly improved for all age groups,
improvements in 5-year survival were confined to
patients younger than 70 years and in 10-year survival
to those younger than 60 years. In the early years of the
Swedish study younger patients will not have received
autologous stem cell transplants, which has been the
standard consolidation treatment for such patients since
the 1990s. Improvements in the survival of younger
patients are to be expected over this longer 30 year per-
iod. A recent North American study using a model-
b a s e dp r o j e c t i o nm e t h o d[ 1 6 ]f o u n dm u c hl a r g e r
increases in projected survival for the younger age
group of below 45 years, than for the older patients
above 60 years in whom projected increases were much
lower and hardly exceeded the estimates from tradi-
tional survival analysis. A number of other studies have
calculated survival using the Kaplan-Meier method, the
most notable of which are an international study of
10,549 patients from North America, Europe and Japan
[17] and another local study of 855 patients in the
South Thames area [12]. Whilst a direct comparison of
these results is not possible, these two studies confirm
the improved survival for patients diagnosed at a
younger age. Finally we found a tendency for better sur-
vival in patients resident in the most affluent areas,
similar to Rachet and colleagues [13].
The treatment of myeloma has evolved dramatically
over the study period, [18] yet our data and those of
other population-based studies demonstrate that it takes
many years for the promising results obtained from clin-
ical trials on selected patients to translate into signifi-
cant improvement of survival for a population of
unselected patients. Autologous stem cell transplanta-
tion was first introduced in the mid-1980s and devel-
oped to become the standard consolidation therapy for
younger patients over the next decade, [19] probably
accounting for much of the improvement in relative sur-
vival described in patients 59 years and younger in our
series.
The late 1990s saw the beginnings of “novel therapy” for
myeloma with thalidomide, bortezomib and lenalidomide
0
5
10
15
20
25
30
35
40
45
50
d e v i r p e D = 5 4 3 2 t n e u l f f A   = 1
Socio-economic deprivation
%
 
r
e
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
Males
Females
Figure 5 Period analysis of 5-year relative survival by socio-economic deprivation, South East England 2000-2004.
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tory cases [20]. These therapies are no longer novel in that
we know that they can work; the challenge is to apply
them to achieve improved survival on a population basis.
A sS c h e ya r g u e s ,t h e r ei sn or e a s o nw h yt h e s ea g e n t s
should not improve outcome in elderly patients given
their proven efficacy and tolerability in this age-group
[21]. Our data begin to show an improvement in relative
survival for those over 60, possibly a result of the wider
and earlier application of thalidomide in particular across
the UK.
A key focus of current research is maximizing com-
plete response and remission in myeloma, which extra-
polating from other haematological malignancies, may
t r a n s l a t ee v e n t u a l l yi n t oc u r eo ft h i sd i s e a s e[ 2 2 ] .T h u s
it is important to note that not only 1-year relative sur-
vival but also 5-year survival are improved in both
younger and older patients in our series. Continued
improvement will require further clinical studies to
explore how best to combine newer agents with conven-
tional therapies, but will also require extension of the
registry approach to ensure that the full impact of treat-
ments on unselected patients is assessed and used to
support sustained funding for these treatments. Integra-
tion of continuing clinical treatment data with tradi-
tional cancer registration methods will enable analysis of
the specific interventions for improved survival. In addi-
tion, a significant proportion (11%) of the population of
London is known to be of black ethnicity, (2001 Census)
and it is now well established that incidence of multiple
myeloma is higher in black ethnic groups [23,4,5]. Stu-
dies in the UK should investigate the relationship
between ethnicity and survival.
Limitations of the study
Figures for the incidence of multiple myeloma by PCT
of residence must be interpreted with care as case ascer-
tainment may have varied across them, particularly as
the South Thames Haematology Register covered only
p a r to ft h ea r e ad u r i n gt h es t u d yp e r i o d .I na d d i t i o n
London is the most ethnically diverse part of the UK,
this study has not investigated the influence of ethnicity
on incidence and survival. We reported no treatment
analyses because only limited details of treatment
received during the six months after diagnosis are col-
lected for cancer registration purposes. Data on impor-
tant new therapies and stem cell transplantation
received after this time are therefore incomplete.
Conclusions
The trends in incidence of multiple myeloma in males
and females are similar to that reported from other wes-
tern populations. No obvious geographical pattern of
incidence by primary care trust emerged. Patients in
affluent areas tended to have a better survival. Relative
survival was longer for younger patients although we
found significant improvements in survival for male
patients over 60 years old. The improved survival
demonstrated for patients of all ages is likely to reflect
increased detection, earlier diagnosis and the introduc-
tion of new treatments.
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